Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401707 · ClinicalTrials.gov registry record · Phase 2
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
A Phase 2 study of Seizures and Status Epilepticus, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06401707: Recruiting Phase 2 study of Seizures and Status Epilepticus, sponsored by University of California, San Francisco.
NCT06401707 is a Phase 2 study of Seizures and Status Epilepticus that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 52 participants, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06401707, a Phase 2 study of Seizures and Status Epilepticus, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.
Primary Outcome
percentage of participants who are able to complete the 5-day course of perampanel or placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Perampanel
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2026-10-20 |
| Phase | Phase 2 |
What NCT06401707 shows while recruiting
NCT06401707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Seizures appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06401707 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06401707 about?
NCT06401707 is a clinical study titled "PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest". Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of per...
What is the current status of trial NCT06401707?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2024-05-20. Estimated completion is 2026-10-20.
What conditions does trial NCT06401707 study?
This clinical trial studies the following conditions: Seizures, Status Epilepticus, Heart Arrest.
What interventions are being tested in trial NCT06401707?
The interventions under investigation include: Placebo (DRUG), Perampanel (DRUG).
Who is sponsoring clinical trial NCT06401707?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401707 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06401707's enrollment target sits among peer trials
52 25th of 39 higher than 15 of 39 other Seizures trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seizures trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
RECRUITING · Phase 2
-
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
COMPLETED · Phase 2
-
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI